Melanoma

Groundbreaking studies reveal the potential of cell therapies to achieve long-term remission in HPV-associated cancers, transforming treatment options for patients.

New clinical trial data highlight the promising antitumor effects of imneskibart combined with aldesleukin in patients with melanoma and NSCLC.

Vishal A. Patel, MD, discusses the FDA approval of cemiplimab in cutaneous squamous cell carcinoma.

A phase 2 trial yielded encouraging results for pembrolizumab plus lenvatinib in uveal melanoma, showing promising progression-free survival rates.

New findings from the CheckMate 238 trial highlight nivolumab's superior long-term efficacy over ipilimumab in treating advanced melanoma.

BNT111 combined with cemiplimab shows promising efficacy in treating PD-(L)1-relapsed melanoma, achieving significant response rates and manageable safety profiles.

A new study shows mRNA-4359 combined with pembrolizumab offers promising results for melanoma patients resistant to prior therapies.

The FDA fast-tracks WTX-124, a promising therapy for advanced melanoma, aiming to improve treatment options for patients with limited choices.

A phase 1 study reveals promising safety and efficacy of NBTXR3 combined with radiotherapy and immunotherapy for resistant melanoma patients.

A new study reveals that multiple tattoos may lower melanoma risk, challenging previous beliefs about tattooing and skin cancer.

FDA advises against BLA submission for IO Biotech's melanoma vaccine after phase 3 trial results narrowly missed statistical significance.

During a live event, Michael C. Lowe, MD, MA, discussed how lifileucel provides an option for patients with unresectable or metastatic melanoma.

Combination therapy with relatlimab and nivolumab enhances treatment-free survival in advanced melanoma, offering promising outcomes over monotherapy.

Adoptive cell therapy with tumor-infiltrating lymphocytes shows promise for advanced melanoma patients unresponsive to existing treatments, offering tailored immunotherapy options.

The FDA approves subcutaneous pembrolizumab, enhancing treatment efficiency for solid tumor treatment while maintaining safety and efficacy.

Replimune navigates FDA challenges for RP1, an innovative melanoma treatment, while emphasizing the urgent need for effective therapies in advanced cases.

A new study reveals that combining vitrectomy and silicone oil with plaque brachytherapy may enhance survival rates in uveal melanoma patients.

Neoadjuvant darovasertib showed promising tumor shrinkage in patients with uveal melanoma.

Nemvaleukin alfa shows promising antitumor activity in advanced melanoma and renal cell carcinoma, with manageable safety in heavily pretreated patients.

High Ki-67 expression predicts poorer survival in patients with acral melanoma, a rare subtype in which Ki-67's predictive value had not been established.

New studies reveal how the DecisionDx-SCC test enhances treatment decisions for high-risk cutaneous squamous cell carcinoma, improving patient outcomes.

Neoadjuvant relatlimab plus nivolumab showed sustained and robust activity in resectable melanoma with potential biomarkers on the horizon.

A systemic review of patient-reported outcome measures used in melanoma research and clinical practice reveals high heterogeneity and gaps in melanoma-specific validation data.

Pembrolizumab showed strong anti-tumor activity in patients with unresectable desmoplastic melanoma.

A phase 3 study shows Cylembio combined with pembrolizumab improves progression-free survival in advanced melanoma, highlighting its potential as a treatment option.